Hypersomnia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NINDS: ⁵² Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary: Hypersomnia, also known as hypersomnolence due to substances including medications, is related to kleine-levin hibernation syndrome and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, snoring and sleep disturbances. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1). The drugs Sodium oxybate and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and hypothalamus, and related phenotypes are Decreased viability and nervous system

Wikipedia: ⁷⁵ Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can... more...

Sources

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)

#	Related Disease	Score	Top Affiliating Genes
1	kleine-levin hibernation syndrome	32.0	HLA-DQB1 HCRT
2	recurrent hypersomnia	31.9	HLA-DQB1 HCRT
3	idiopathic hypersomnia	31.4	PTGDS OPN4 HLA-DQB1 HCRT
4	sleep disorder	30.9	OPN4 HLA-DQB1 HCRT
5	narcolepsy 1	30.8	HLA-DQB1 HCRT
6	narcolepsy	30.7	PTGDS HLA-DQB1 HCRT
7	narcolepsy 2	30.5	HLA-DQB1 HCRT
8	neuromyelitis optica	29.9	HLA-DQB1 HCRT
9	periodic limb movement disorder	29.4	HLA-DQB1 HCRT
10	delayed sleep phase disorder	29.3	OPN4 HCRT
11	migraine with or without aura 1	29.2	OPN4 HCRT
12	guillain-barre syndrome	29.2	HLA-DQB1 HCRT
13	major depressive disorder	11.0
14	dystonia, dopa-responsive, due to sepiapterin reductase deficiency	11.0
15	myotonic dystrophy 2	10.9
16	atypical depressive disorder	10.9
17	cranioectodermal dysplasia	10.5
18	sleep apnea	10.5
19	apnea, obstructive sleep	10.4
20	bipolar disorder	10.4
21	mood disorder	10.3
22	myotonic dystrophy 1	10.2
23	obesity-hypoventilation syndrome	10.2
24	bulimia nervosa	10.2
25	encephalitis	10.1
26	encephalopathy	10.1
27	restless legs syndrome	10.1
28	dysthymic disorder	10.1
29	movement disease	10.1
30	traumatic brain injury	10.1
31	prader-willi syndrome	10.0
32	ocular motor apraxia	10.0
33	kearns-sayre syndrome	10.0
34	congenital central hypoventilation syndrome	10.0
35	brain cancer	10.0
36	acute disseminated encephalomyelitis	10.0
37	rem sleep behavior disorder	10.0
38	multiple sclerosis	10.0
39	attention deficit-hyperactivity disorder	10.0
40	anxiety	10.0
41	autonomic nervous system disease	10.0
42	endogenous depression	10.0
43	pfeiffer syndrome	9.9
44	tobacco addiction	9.9
45	major affective disorder 2	9.9
46	stroke, ischemic	9.9
47	restless legs syndrome 6	9.9
48	major affective disorder 7	9.9
49	limbic encephalitis	9.9
50	central diabetes insipidus	9.9

Graphical network of the top 20 diseases related to Hypersomnia:

Sources

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:

excessive daytime somnolence; snoring; sleep disturbances; sleeplessness; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified; [d]sleep disturbances (& [hypersomnia] or [insomnia])

GenomeRNAi Phenotypes related to Hypersomnia according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00249-S	9.1	OPN4
2	Decreased viability	GR00381-A-1	9.1	HLA-DQB1 OPN4
3	Decreased viability	GR00381-A-3	9.1	HLA-DQB1 OPN4
4	Decreased viability	GR00402-S-2	9.1	HLA-DQB1

MGI Mouse Phenotypes related to Hypersomnia:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	8.92	HCRT HLA-DQB1 OPN4 PTGDS

Sources

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Sodium oxybate

Approved

Phase 2, Phase 3

502-85-2

23663870

2

Sodium citrate

Approved, Investigational

Phase 2, Phase 3

68-04-2

23431961

3

Histamine

Approved, Investigational

Phase 3

51-45-6

774

4

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

77-92-9

311

5

Anesthetics, Intravenous

Phase 2, Phase 3

6

Anesthetics, General

Phase 2, Phase 3

7

Anesthetics

Phase 2, Phase 3

8

Pharmaceutical Solutions

Phase 2, Phase 3

9

Citrate

Phase 2, Phase 3

10

Histamine phosphate

Phase 3

51-74-1

134614

11

Flumazenil

Approved

Phase 1, Phase 2

78755-81-4

3373

12

Clarithromycin

Approved

Phase 2

81103-11-9

84029

13

Dextroamphetamine

Approved, Illicit, Investigational

Phase 2

51-64-9, 300-62-9

5826 3007

14

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

15

Modafinil

Approved, Investigational

Phase 2

68693-11-8

4236

16

Pentetrazol

Experimental, Withdrawn

Phase 2

54-95-5

17

Convulsants

Phase 2

18

Antidotes

Phase 1, Phase 2

19

GABA Modulators

Phase 1, Phase 2

20

Protective Agents

Phase 1, Phase 2

21

Neurotransmitter Agents

Phase 2

22

Anti-Bacterial Agents

Phase 2

23

Anti-Infective Agents

Phase 2

24

Cytochrome P-450 Enzyme Inhibitors

Phase 2

25

Cytochrome P-450 CYP3A Inhibitors

Phase 2

26

Central Nervous System Stimulants

Phase 2

27

Antibiotics, Antitubercular

Phase 2

28

Adrenergic Agents

Phase 2

29

Dopamine Uptake Inhibitors

Phase 2

30

Adderall

Phase 2

31

Dopamine Agents

Phase 2

32

Sympathomimetics

Phase 2

33

Caffeine

Approved

58-08-2

2519

34

Melatonin

Approved, Nutraceutical, Vet_approved

73-31-4

896

Interventional clinical trials:

(show all 45)

#	Name	Status	NCT ID	Phase	Drugs
1	A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension	Completed	NCT03533114	Phase 3	JZP-258;Placebo Oral Solution
2	The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study	Completed	NCT03682185	Phase 3
3	A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia	Recruiting	NCT05156047	Phase 3	Pitolisant Oral Tablet;Placebo oral tablet
4	A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia	Recruiting	NCT03597555	Phase 2, Phase 3	Sodium Oxybate Oral Solution 500 MG/ML;Placebos
5	An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010	Enrolling by invitation	NCT05458128	Phase 3	pitolisant
6	A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia	Unknown status	NCT03542851	Phase 2	Pentetrazol (PTZ);Placebo oral capsule
7	A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors	Completed	NCT01183312	Phase 1, Phase 2	Flumazenil
8	Clarithromycin for the Treatment of Hypersomnia	Completed	NCT01146600	Phase 2	Clarithromycin followed by placebo;Placebo then Clarithromycin
9	A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2	Completed	NCT02512588	Phase 2	BTD-001;Placebo
10	Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes	Recruiting	NCT04026958	Phase 2	Clarithromycin;Placebo
11	Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines	Recruiting	NCT03772314	Phase 2	Modafinil;Amphetamine-Dextroamphetamine
12	A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia	Completed	NCT04091438	Phase 1	TAK-925;TAK-925 Placebo
13	Hypersomnia in Major Depressive Disorder	Unknown status	NCT04006834
14	Prevalence and Characteristics of Sleep Disturbances Among Psychiatric Inpatients	Unknown status	NCT04201392
15	Effects of Telemedicine and Humidification for Continous Positive Airway Pressure (CPAP) in OSAS.	Unknown status	NCT04300166
16	Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia	Completed	NCT03459300
17	Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia.	Completed	NCT01926405
18	Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial	Completed	NCT03904238
19	Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1	Completed	NCT04634682
20	Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia	Completed	NCT02913651
21	Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation	Completed	NCT01719315
22	The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol	Completed	NCT03356938
23	Anesthetic Management of Patients With Chronic Sleep Disorders	Completed	NCT04827329
24	Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)	Completed	NCT02037438
25	Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases	Completed	NCT01877616
26	The Feasibility of a Tailored Music Intervention to Reduce Symptoms of Sleep Disruption in Older Adults With Dementia	Completed	NCT04157244
27	Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders	Completed	NCT00001664
28	Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.	Completed	NCT00916253		Modafinil;Placebo
29	The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder	Completed	NCT01764035
30	Coordination of Rare Diseases at Sanford	Recruiting	NCT01793168
31	Analysis of New Salivary Biomarkers to Evaluate Excessive Diurnal Sleepiness in Children With Hypersomnia	Recruiting	NCT05183464
32	Swiss Primary Hypersomnolence and Narcolepsy Cohort Study	Recruiting	NCT04330963
33	Study on Disease Course and Quality of Life in Patients With Sleep Disorders (Mainz Sleep Registry)	Recruiting	NCT05321355
34	A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study	Recruiting	NCT05443373
35	Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders	Active, not recruiting	NCT03018912
36	Idiopathic Hypersomnia - a Retrospective Characterization Study	Enrolling by invitation	NCT05150977
37	Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments	Enrolling by invitation	NCT05371483
38	Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia	Not yet recruiting	NCT05627388
39	Multiple Reaction Monitoring (MRM) Versus I 125 Radioimmunoassay (RIA) for the Quantification of Orexin-A/Hypocretin-1 Levels in Cerebrospinal Fluid: a Prospective Diagnostic Validation Study in Patients With Hypersomnolence	Not yet recruiting	NCT05615584
40	Randomized Control Trial to Compare Patient Outcomes Following Unattended Polysomnography Versus In-lab Polysomnography for Sleep Apnea and Comorbid Sleep Disorders	Not yet recruiting	NCT05230394
41	Disrupted Sleep in the Elderly: Light Exposure Studies	Suspended	NCT00427323
42	'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'	Suspended	NCT04419792
43	Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy	Terminated	NCT03198156
44	Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease	Terminated	NCT01544465
45	Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia	Withdrawn	NCT03626727	Early Phase 1	Sodium Oxybate Oral Solution [Xyrem]

Search NIH Clinical Center for Hypersomnia

Sources

Genetic Tests for Hypersomnia

Sources

Anatomical Context for Hypersomnia

Organs/tissues related to Hypersomnia:

MalaCards : Brain, Heart, Hypothalamus, Thalamus, Prefrontal Cortex, Eye, Globus Pallidus

Sources

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 2061)

#	Title	Authors	PMID	Year
1	Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric patients with sleep-related problems. ⁶²	Okada I...Ozaki N	35029795	2022
2	Associations of somatic depressive symptoms with body mass index, systemic inflammation, and insulin resistance in primary care patients with depression. ⁶²	Shell AL...Stewart JC	36074315	2022
3	Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures. ⁶²	Cesari M...Heidbreder A	36455881	2022
4	Clinical considerations for the diagnosis of idiopathic hypersomnia. ⁶²	Dauvilliers Y...Thorpy MJ	36401976	2022
5	Association between blood pressure and parameters related to sleep disorders in Tabari cohort population. ⁶²	Rezapour M...Hosseini SH	36376986	2022
6	Symmetrical isolated globus pallidus infarction due to bilateral carotid artery dissection. ⁶²	Trandafir C...Ion IM	35915270	2022
7	Central hypersomnia and chronic insomnia: expanding the spectrum of sleep disorders in long COVID syndrome - a prospective cohort study. ⁶²	Moura AEF...Sobreira-Neto MA	36352367	2022
8	Sleep outcomes in pediatric mild traumatic brain injury: a systematic review and meta-analysis of prevalence and contributing factors. ⁶²	Djukic S...Lah S	36413091	2022
9	Central Disorders of Hypersomnolence: Association with Fatigue, Depression and Sleep Inertia Prevailing in Women. ⁶²	Nevsimalova S...Sonka K	36358417	2022
10	Sociodemographic, lifestyle and clinical characteristics of energy-related depression symptoms: A pooled analysis of 13,965 depressed cases in 8 Dutch cohorts. ⁶²	Vreijling SR...Jansen R	36372132	2022
11	Sleep and circadian rhythm profiles in seasonal depression. ⁶²	Wescott DL...Roecklein KA	36244199	2022
12	Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome. ⁶²	Barateau L...Dauvilliers Y	35918167	2022
13	Sleep and Phelan-McDermid Syndrome: Lessons from the International Registry and the scientific literature. ⁶²	Moffitt BA...Boccuto L	35996993	2022
14	Low carnitine palmitoyltransferase 1 activity is a risk factor for narcolepsy type 1 and other hypersomnia. ⁶²	Honda M...Miyagawa T	35810398	2022
15	Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls. ⁶²	Torstensen EW...Jennum PJ	36427467	2022
16	Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. ⁶²	Ishikawa T...Kimura H	36108771	2022
17	Socioeconomic status and sleep health: a narrative synthesis of three decades of empirical research. ⁶²	Papadopoulos D...Sosso FAE	36239056	2022
18	Is it time for a gold standard in the diagnosis of hypersomnia? ⁶²	Ebrahim IO...Gotts ZM	35924659	2022
19	Excessive daytime sleepiness: an emerging marker of cardiovascular risk. ⁶²	Bock J...Somers V	35102000	2022
20	Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. ⁶²	Sparasci D...Manconi M	36253127	2022
21	Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. ⁶²	Siegler JE...Galetta S	36253129	2022
22	Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study. ⁶²	Dubessy AL...Arnulf I	36253130	2022
23	Central disorders of hypersomnolence: diagnostic discrepancies between military and civilian sleep centers. ⁶²	Thomas CL...Williams S	35855527	2022
24	French Sleepiness Scale for Adolescents-8 items: A discriminant and diagnostic validation. ⁶²	Gustin MP...Franco P	36253180	2022
25	Sleep quality and risk of recurrent aphthous ulcers: A Spanish cohort study. ⁶²	Tohidinik HR...Takkouche B	34242451	2022
26	Comparison of the efficacy of ultrasound-guided erector spinae plane block and thoracic paravertebral block combined with intercostal nerve block for pain management in video-assisted thoracoscopic surgery: a prospective, randomized, controlled clinical trial. ⁶²	Sun L...He H	36088297	2022
27	Orexin Receptor Agonists as Possible Treatment for Narcolepsy and Idiopathic Hypersomnia. ⁶²	Abdel-Magid AF	36105332	2022
28	Precision Medicine for Idiopathic Hypersomnia. ⁶²	Arnulf I...Dodet P	36150801	2022
29	Diabetes, sleep disorders and risk of depression - A Danish register-based cohort study. ⁶²	Wium-Andersen IK...Wium-Andersen MK	35932548	2022
30	Pharmacologic Management of Excessive Daytime Sleepiness. ⁶²	Ono T...Nishino S	36150809	2022
31	Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort. ⁶²	Mutti C...Plazzi G	35750949	2022
32	Altered Behavioral Responses Show GABA Sensitivity in Muscleblind-Like 2-Deficient Mice: Implications for CNS Symptoms in Myotonic Dystrophy. ⁶²	Edokpolor KS...Bassell GJ	36150891	2022
33	Kleine-Levin syndrome: report of a case with marked dysautonomic features. ⁶²	Fiamingo G...Terzaghi M	35393940	2022
34	Proteomic biomarkers of Kleine-Levin syndrome. ⁶²	Hedou J...Mignot E	35859339	2022
35	Understanding and approaching excessive daytime sleepiness. ⁶²	Perez-Carbonell L...Dauvilliers Y	36115367	2022
36	Leigh-Like Syndrome With a Novel, Complex Phenotype Due to m.10191T>C in Mt-ND3. ⁶²	Newstead SM...Finsterer J	36249637	2022
37	Sleepiness in obstructive sleep apnea using hypopneas defined by a 3% oxygen desaturation or arousal but not by 4% or greater oxygen desaturation. ⁶²	Budhiraja R...Quan SF	34564819	2022
38	Sleep disorders in children with asthma. ⁶²	Reiter J...Forno E	33647191	2022
39	Parental burnout and sleep problems in Iranian mothers of primary school-aged children: Exploring the mediation effect of emotional schemas. ⁶²	Hormozi BK...Sabzi N	35849708	2022
40	[Cognitive disorders and sleep disturbances in long COVID]. ⁶²	Schilling C...Schweiger JI	35576015	2022
41	Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. ⁶²	Bijlenga D...Lammers GJ	35429267	2022
42	[Diagnostic strategy for hypersomnolence disorders]. ⁶²	Leclair-Visonneau L	35184867	2022
43	Recognizing New-Onset Sleep Disorders in Autoimmune Encephalitis Often Prompt Earlier Diagnosis. ⁶²	Ralls F...Grigg-Damberger MM	35239557	2022
44	Prevalence, Incidence and Health Impacts of Sleep Disorders on Coronary Artery Disease Risk Factors: Results of a Community-Based Cohort Study (KERCADRS). ⁶²	Najafipour H...Mirzazadeh A	36474691	2022
45	Mental Health Conditions According to Stress and Sleep Disorders. ⁶²	Merrill RM	35805615	2022
46	Diagnosis and management of sleep disorders in Prader-Willi syndrome. ⁶²	Duis J...Revana A	35172921	2022
47	Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong. ⁶²	Li X...Wong ICK	35461018	2022
48	Comparative polysomnography parameters between narcolepsy type 1/type 2 and idiopathic hypersomnia: A systematic review and meta-analysis. ⁶²	Zhang Y...Sanford LD	35278894	2022
49	IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. ⁶²	Alroobaea R...Bragazzi NL	35731078	2022
50	Dynamic networks of psychological symptoms, impairment, substance use, and social support: The evolution of psychopathology among emerging adults. ⁶²	Crouse JJ...Hickie IB	35694845	2022

Sources

Genes for Hypersomnia

Genes related to Hypersomnia (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	8.08	GeneCards inferred via : Publications (show sections)
2	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	7.8	GeneCards inferred via : Publications (show sections)
3	OPN4	Opsin 4	Protein Coding	7.36	GeneCards inferred via : Publications (show sections)
4	PTGDS	Prostaglandin D2 Synthase	Protein Coding	7.36	GeneCards inferred via : Publications (show sections)

Sources

Variations for Hypersomnia

Sources

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Sources

Pathways for Hypersomnia

Sources

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	rough endoplasmic reticulum	GO:0005791	8.92	PTGDS HCRT

Sources

Sources for Hypersomnia

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: HYP263 MIFTS: 37	Hypersomnia Categories: Mental diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables